Home
About
About CPD Network
Mission & Vision
Purpose
Governance
Compliance
Physician Organization Checklist
Microsites
Members
Experts
Contact
Login
Home
About
About CPD Network
Mission & Vision
Purpose
Governance
Compliance
Physician Organization Checklist
Microsites
Members
Experts
Contact
Login
Home
Microsites
Talk Of The Town
FR
EN
Expert Tips for Primary Care
Outcome Reduction Summary by Patient Type
Program Slides
Reference List
Other Resources and Tools
Diabetes Canada Pharmacologic Management: 2020 Update
Diabetes Canada Pharmacologic Management: 2020 Update – User’s Guide
2020 Clinical Practice Guidelines - Quick Reference Guide
Antihyperglycemic Agents and Renal Function
KDIGO Clinical Practice Guideline for the Evaluation and Management of CKD
Sick-Day Medication List
Pharmacotherapy for Type 2 Diabetes Interactive Tool
Reducing Vascular Risk Interactive Tool
Self-Monitoring Blood Glucose (SMBG) Interactive Tool
Articles
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes (EMPA-REG OUTCOME)
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes (CANVAS)
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes (DECLARE)
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6)
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes (LEADER)
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy (CREDENCE)
Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND)
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction (DAPA-HF)
Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure (EMPEROR-Reduced)
Dapagliflozin in Patients with Chronic Kidney Disease (DAPA-CKD)
Check your downloads!
Please click 'Login' and enter your access code
cpdisup
